Previous studies have suggested that benralizumab could help improve lung function and reduce asthma exacerbations among patients with severe, uncontrolled asthma. In a recent study, researchers...
Researchers investigated the correlation and predictive relationship between fractional exhaled nitric oxide levels and sputum eosinophils in patients with COPD.
Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, is safe and effective in treatment of severe uncontrolled, eosinophilic asthma, according to two new industry-funded studies.
